多发性硬化患者全髋关节置换术后不良结局发生率是否更高
本研究比较了2008年1月至2016年6月间在本机构接受初次全髋关节置换术的多发性硬化患者(34例41髋)与按年龄、体重指数和Charlson/Deyo评分1:2匹配的无多发性硬化全髋关节置换患者队列。结果显示多发性硬化患者8年假体生存率更低(91.5% vs 98.7%,p=0.033)、功能评分更低、物理治疗时间更长、并发症更多(6例 vs 0例,p<0.001)。
要点
- 多发性硬化患者全髋关节置换术后8年假体生存率低于匹配队列(91.5% vs 98.7%,p=0.033)。
- 多发性硬化患者改良Harris髋关节评分(66 vs 80,p<0.001)和HOOS JR评分(79 vs 88,p=0.009)均低于匹配队列。
- 多发性硬化患者并发症更多(6例 vs 0例,p<0.001),物理治疗时间更长(5周 vs 3周,p=0.002),恢复至基线功能时间更长(7周 vs 5周,p=0.010)。
核心结论
- 多发性硬化患者全髋关节置换术后假体生存率更低、功能结局评分更低、并发症发生率更高,且恢复至基线功能水平所需时间更长。
研究设计与样本
- 回顾性队列研究,比较本机构2008年1月至2016年6月间接受初次全髋关节置换术的多发性硬化患者(34例41髋)与按年龄、体重指数和Charlson/Deyo评分1:2匹配的无多发性硬化全髋关节置换患者队列。
主要发现
- 多发性硬化组8年全因假体生存率为91.5%(95%CI 82.7至100),匹配队列为98.7%(95%CI 96.2至100),p=0.033。
- 多发性硬化组改良Harris髋关节评分为66,匹配队列为80,p<0.001;HOOS JR评分多发性硬化组为79,匹配队列为88,p=0.009。
- 多发性硬化组物理治疗时间为5周,匹配队列为3周,p=0.002;恢复至基线时间多发性硬化组为7周,匹配队列为5周,p=0.010。
- 多发性硬化组并发症为6例,无多发性硬化组为0例,p<0.001。
- 多发性硬化组改良多发性硬化影响量表评分从2.9恶化至3.4,p=0.008。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study compared multiple sclerosis (MS) patients who underwent primary total hip arthroplasty (THA) with a matched cohort. Specifically, we evaluated: 1) implant survivorship; 2) functional outcomes (modified Harris Hip Scores (mHHS), Hip Disability and Osteoarthritis Outcome Score, Joint Replacement (HOOS JR), and modified Multiple Sclerosis Impact Scale (mMSIS) scores (with the MS cohort also evaluated based on the disease phenotype)); 3) physical therapy duration and return to function; 4) radiographic outcomes; and 5) complications. PATIENTS AND METHODS: We reviewed our institution's database to identify MS patients who underwent THA between January 2008 and June 2016. A total of 34 MS patients (41 hips) were matched in a 1:2 ratio to a cohort of THA patients who did not have MS, based on age, body mass index (BMI), and Charlson/Deyo score. Patient records were reviewed for complications, and their functional outcomes and radiographs were reviewed at their most recent follow-up. RESULTS: Compared with the matched cohort, MS patients had lower all-cause implant survivorship at eight years (91.5% (95% confidence interval (CI) 82.7 to 100) vs 98.7% (95% CI 96.2 to 100)) (p = 0.033), lower mHHS scores (66 vs 80, p < 0.001), and HOOS JR scores (79 vs 88, p = 0.009). Multiple sclerosis patients also required more physiotherapy (five weeks vs three weeks, p = 0.002) and took longer to return to baseline (seven weeks vs five weeks, p = 0.010) than the matched cohort. Furthermore, MS patients had more complications than the non-MS patients (six vs zero, p < 0.001). The worse outcomes of the MS group can potentially be explained by predisposition of these patients to mechanical complications and progression of their disease during the period of this study, as demonstrated by worsening of the mMSIS scores (2.9 vs 3.4; p = 0.008). CONCLUSION: MS patients had lower implant survivorship, lower functional outcome scores, and increased complication rates; in addition, MS patients took longer to return to their baseline functional level after THA. Cite this article: Bone Joint J 2018;100-B:875-81.
引用
- Newman JM, Khlopas A, Sodhi N, et al. Are adverse outcome rates higher in multiple sclerosis patients after total hip arthroplasty? Bone Joint J. 2018. PMID: 29954205. doi:10.1302/0301-620X.100B7.BJJ-2017-1569.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。